Biologics

In July, caplacizumab received FDA fast track status for treating thrombotic thrombocytopenic purpura (aTTP), an orphan blood disease affecting 7,500 US Americans per year. Now, Ablynx …

Biosimilar medicines have the potential to foster unprecedented access to several vital biologics used to treat serious diseases such as rheumatoid arthritis and cancer – coming …

There is no sign of a summer slump for Copenhagen-based biotech Genmab. In July, it received BTD for its lead candidate daratumumab (Darzalex), a monoantibody for …

Just days after shelling out US$14bn (€12.4bn) for fought-over Californian biotech Medivation, Pfizer is taking AstraZeneca’s antibiotics business off the British-Swedish pharma company’s hands. AZ will …

The fund has drawn interest from international investors, insurance companies and family offices, alongside the Biotech & Healthcare Acceleration Fund (FABS) operated by Bpifrance in the …

Six months ago, it was not clear if Apeiron biologics would market its neuroblastoma treatment dinutuximab beta on its own or through a partnership, according to …

At the largest pharma and biotech meeting ever in Barcelona, CPhI organiser UBM presented several huge growth opportunities by 2021 within its annual report: A first …

Roche’s NSLC mAb outperforms chemo Source link

Before joining TxCell, he worked at the Chinese immuno-oncology company ZMKS International Cancer Therapy Biotechnology as CSO and Director of R&D. From 2009 to 2016, Zhou …

The financing was led by new investors ORI Healthcare Fund L.P. (“ORI Fund”) with participation by Shenzhen Hepalink Pharmaceutical Co., Ltd. Already, Kymab can count some …